SOLASTA Bio secures patent and EPA approval
An agri-biotech firm says it has taken “one giant stride” in its route to market with major regulatory and intellectual property wins.
SOLASTA Bio, which develops nature-inspired bioinsecticides, has secured its first patent grant, reinforcing its technology for pest control using insect neuropeptides.
The Glasgow-based company has also received a crucial classification from the US Environmental Protection Agency, streamlining its regulatory path.
The milestones follow a $14 million funding round last year, with bosses saying they will help position SOLASTA Bio “exceptionally well” as it looks to commercialise its eco-friendly insecticides.
Shireen Davies, SOLASTA Bio co-founder and chief executive, said: “These developments represent a major inflection point.
“The combination of strong patent protection and a more efficient regulatory pathway positions us exceptionally well to advance our product development and reach full commercialisation within a few years.
“Our technology has the potential to transform the global crop protection market, and we are now one giant stride closer to realising that vision.”
Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning National email for free.
Ready to scale? Buy-and-build offers opportunity
When will our regional economy grow?
Creating a thriving North East construction sector
Why investors are still backing the North East
Time to stop risking Britain’s family businesses
A year of growth, collaboration and impact
2000 reasons for North East business positivity
How to make your growth strategy deliver in 2026
Powering a new wave of regional screen indies
A new year and a new outlook for property scene
Zero per cent - but maximum brand exposure
We don’t talk about money stress enough